RGNT (Regentis Biomaterials) EBIT: $-13.32 Mil (TTM As of Dec. 2025)

What is Regentis Biomaterials EBIT?

Regentis Biomaterials RGNT -1.19% 14 EBIT is $-13.32 Mil as of Dec. 2025. GuruFocus rates RGNT with a GF Score™ of 14/100. The stock has 2 warning signs investors should review.

Regentis Biomaterials's earnings before interest and taxes (EBIT) for the six months ended in Dec. 2025 was $-10.31 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2025 was $-13.32 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Regentis Biomaterials's annualized ROC % for the quarter that ended in Dec. 2025 was -348.68%. Regentis Biomaterials's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was %.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Regentis Biomaterials's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was -57.87%.

Regentis Biomaterials (AMEX:RGNT) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Regentis Biomaterials's annualized ROC % for the quarter that ended in Dec. 2025 is calculated as:

	ROC % (Q: Dec. 2025 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Jun. 2025 )	+	Invested Capital (Q: Dec. 2025 ))	/ count )
=	-16.36 * ( 1 - 0% )	/	( (8.169	+	1.215)	/ 2 )
=	-16.36	/	4.692
=	-348.68 %

where

	Invested Capital		(Q: Jun. 2025 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	0.475	-	1.54	-	( 0.189	-	max(0, 9.709	-	0.475	+	0.189	))
=	8.169

	Invested Capital		(Q: Dec. 2025 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	7.618	-	1.659	-	( 7.378	-	max(0, 2.874	-	7.618	+	7.378	))
=	1.215

Note: The Operating Income data used here is two times the semi-annual (Dec. 2025) data.

2. Joel Greenblatt's definition of Return on Capital:

Regentis Biomaterials's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Dec. 2025 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Jun. 2025		Q: Dec. 2025
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-20.61	/	( ( (0 + max(-1.259, 0))	+	(0 + max(-1.667, 0)) )	/	2 )
=	-20.61	/	( ( 0	+	0 )	/	2 )
=	-20.61	/	0
=	%

where Working Capital is:

	Working Capital		(Q: Jun. 2025 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	0.286)	-	(1.54	+	0	+	0.004999999999999)
=	-1.259

	Working Capital		(Q: Dec. 2025 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	0.0099999999999998)	-	(1.659	+	0	+	0.018)
=	-1.667

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Regentis Biomaterials's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Dec. 2025 )
	=	-13.324	/	23.023
	=	-57.87 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Regentis Biomaterials EBIT Related Terms

Regentis Biomaterials EBIT Historical Data

* Premium members only.

The historical data trend for Regentis Biomaterials's EBIT can be seen below:

Regentis Biomaterials EBIT Chart

Regentis Biomaterials Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

EBIT

Get a 7-Day Free Trial

-0.67

-1.45

-3.96

4.97

-13.32

Regentis Biomaterials Semi-Annual Data
	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24	Jun25	Dec25
EBIT	Get a 7-Day Free Trial						-2.75	7.22	-2.24	-3.02	-10.31

RGNT vs MHUAF, LUCY, CUPR: EBIT Comparison

For the Medical Instruments & Supplies subindustry, Regentis Biomaterials's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Regentis Biomaterials EV-to-EBIT vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Regentis Biomaterials's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Regentis Biomaterials's EV-to-EBIT falls into.

Save Embed

14GF Score

Regentis Biomaterials Ltd RGNT

EBIT is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Regentis Biomaterials EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-13.32 Mil.

Frequently Asked Questions Learn more about EBIT →

What does a EBIT of $-13.32 Mil mean?

Regentis Biomaterials (RGNT) has a EBIT of $-13.32 Mil as of Dec. 2025. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Regentis Biomaterials.

Is Regentis Biomaterials' EBIT too high?

Regentis Biomaterials' current EBIT is $-13.32 Mil. Overall, Regentis Biomaterials has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.

How does Regentis Biomaterials' EBIT compare to MHUAF and LUCY?

Regentis Biomaterials' EBIT of $-13.32 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good EBIT for a Medical Devices & Instruments company?

A good EBIT depends on the Medical Devices & Instruments industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high EBIT mean?

A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Regentis Biomaterials. Regentis Biomaterials's current EBIT is $-13.32 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Regentis Biomaterials stock overvalued right now?

Regentis Biomaterials (RGNT) has a current EBIT of $-13.32 Mil. The current EBIT is $-13.32 Mil. Regentis Biomaterials' overall GF Score™ is 14/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is EBIT calculated?

EBIT is calculated from a company's financial statements. For Regentis Biomaterials (RGNT), the current EBIT is $-13.32 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Regentis Biomaterials Business Description

Industry Healthcare Medical Devices & Instruments

Comparable Companies MHUAF LUCY CUPR NXGL CBSC BNGO RSCF GCTK UEEC ZJYL ISRG XPAR:EL TSE:7741 BDX XSWX:ALC MDLN RMD WST TSE:4543 XPAR:DIM

Address 60, Medinat Hyahudim, Entrance C, Herzlia Pituach, ISR, 4676652

Website https://www.regentis.co.il

Regentis Biomaterials Ltd is a regenerative medicine company dedicated to developing tissue repair solutions that restore health and enhance the quality of life of patients. It is focused on orthopedic treatments using its Gelrin platform based on degradable hydrogel implants to regenerate damaged or diseased tissue (inflamed cartilage and bone tissue). Gelrin is a hydrogel matrix of polyethylene glycol diacrylate and denatured fibrinogen (a biologically inactivated protein that normally has a role in blood clotting). Its product is GelrinC, a cell-free, off-the-shelf hydrogel that is cured into an implant in the knee for the treatment of painful injuries to articular knee cartilage.

14GF Score

Get the complete analysis for RGNT

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.15

Price

View RGNT Analysis

See EBIT data for all stocks →